Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | AKT2 | P31751 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13996075 | 0.84 | MEN1 (0.62) | L3MBTL1CYP1A2MEN1KMT2ARAB9A | |
| SCHEMBL28353612 | 0.83 | ADORA2A (0.48) | MEN1KMT2ARAB9ACYP11B2ADORA1 | |
| SCHEMBL19556523 | 0.82 | CYP2A6 (0.52) | CYP1A2CYP11B2CYP11B1METAP2MAPK1 | |
| SCHEMBL28122030 | 0.81 | ALDH1A1 (0.56) | MEN1KMT2ARAB9ACYP11B2CYP11B1 | |
| SCHEMBL5647023 | 0.79 | CYP11B1 (0.47) | L3MBTL1MEN1KMT2ARAB9ACYP11B2 | |
| SCHEMBL5646654 | 0.79 | RAB9A (0.46) | L3MBTL1MEN1KMT2ARAB9AMETAP2 | |
| SCHEMBL20663072 | 0.78 | RAB9A (0.44) | L3MBTL1CYP1A2MEN1KMT2ARAB9A | |
| SCHEMBL11516493 | 0.78 | CHEK1 (0.46) | L3MBTL1CYP1A2MEN1KMT2ARAB9A | |
| SCHEMBL27609611 | 0.75 | ASIC3 (0.46) | AKT2ADORA1ATMCHEK1SMN1; SMN2 | |
| SCHEMBL5646784 | 0.75 | KIF11 (0.47) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288589-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-09-18 | — | — | US | disclosed |
| EP-4444289-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107592-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107592-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-10000456-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| CN-106397415-A | Pyridine-based five-membered-ring substituted compound and application thereof | 江苏三月光电科技有限公司 | 2017-02-15 | — | — | CN | disclosed |
| EP-2483251-B1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2483251-B1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| CN-102656168-B | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS INC | 2015-04-01 | — | — | CN | disclosed |
| CN-102770415-B | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS INC | 2014-09-24 | — | — | CN | disclosed |
| US-20130072490-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072490-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. (US) | 2013-03-21 | — | — | US | disclosed |
| CN-102770415-A | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS INC | 2012-11-07 | — | — | CN | disclosed |
| CN-102656168-A | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS INC | 2012-09-05 | — | — | CN | disclosed |
| EP-2483251-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | Amira Pharmaceuticals, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2483269-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | Amira Pharmaceuticals, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20110082164-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011041461-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041462-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041462-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072490-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | L3MBTL1 2315/4885CYP1A2 4291/4885MEN1 1811/4885 |
| US-20110082164-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | L3MBTL1 2315/4885CYP1A2 4291/4885MEN1 1811/4885 |
| US-20250288589-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | L3MBTL1 1728/4885CYP1A2 837/4885MEN1 3232/4885 |
| US-10000456-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | LPAR1, LPAR2, LPAR4 | L3MBTL1 2315/4885CYP1A2 4291/4885MEN1 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.